Clinical and Experimental Rheumatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Use and perceptions of nutrition information resources in systemic sclerosis: a Scleroderma Patient-centred Intervention Network (SPIN) cohort study
CONCLUSIONS: Respondents used many different diet and nutrition information resources. They preferred resources from conventional health care providers, affiliated with credible institutions (e.g., SSc patient organisations), or with personal connections (e.g., SSc support groups). Future research should address the limited evidence base on nutrition in SSc and assess the quality of information provided by different information resources.PMID:38573100 | DOI:10.55563/clinexprheumatol/dt5hae (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - April 4, 2024 Category: Rheumatology Authors: Nora Østbø Elizabeth Yakes Jimenez Marie-Eve Carrier Linda Kwakkenbos Brett Thombs Scleroderma Patient-centred Intervention Network (SPIN) Diet and Nutrition Education Patient Advisory Team, on behalf of the SPIN Investigators Source Type: research

Systemic lupus erythematosus: one year in review 2024
Clin Exp Rheumatol. 2024 Mar;42(3):583-592. doi: 10.55563/clinexprheumatol/mnvmvo. Epub 2024 Mar 27.ABSTRACTSystemic lupus erythematosus (SLE) is classically regarded as the landmark of systemic autoimmune diseases, characterised by protean, multi-systemic manifestations and a highly variable clinical course.Over the last years, both clinical and translational clinical research efforts led to significant steps forward in management and treatment of SLE. However, numerous aspects of SLE, from pathogenesis to treatment, still remain challenging, and several unmet needs persist for both patients and physicians. Following the ...
Source: Clinical and Experimental Rheumatology - March 28, 2024 Category: Rheumatology Authors: Davide Schilir ò Ettore Silvagni Benedetta Cirib è Federico Fattorini Vincenzo Maccarrone Elena Elefante Viola Signorini Dina Zucchi Chiara Cardelli Alessandra Bortoluzzi Chiara Tani Source Type: research

Anti-SSA Ro52 and anti-Ro60 autoantibodies: association with clinical phenotypes
CONCLUSIONS: Anti-Ro52+ antibody alone is frequently found in patients with non-rheumatic diseases. In addition, anti-Ro52+ antibody is also prevalent in patients with CTD and associated with clinical phenotypes that are different from anti-Ro60+ antibody.PMID:38530658 | DOI:10.55563/clinexprheumatol/puxml7 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 26, 2024 Category: Rheumatology Authors: Carolina Mazeda Natacha Oliveira Catarina Abreu Vanessa Fraga Isabel Maduro Andr é Saraiva Lu ís Inês Carla Ferreira Ana Margarida Correia Rafaela Nicolau Filipa Farinha Ingrid Villanueva Diogo Jesus Pedro Abreu Agna Neto Joana Silva Dinis Anabela Barc Source Type: research

Detection of IgE-autoantibodies to nuclear antigens in patients with systemic sclerosis and analysis of their clinical relevance
CONCLUSIONS: IgE-autoantibodies against CENP-A/B and topo-I occur in SSc underlining the concept that SSc may be a T helper cell type 2 mediated disease. IgE-anti-CENP-A-antibodies correlated with disease activity, but this has to be confirmed in larger studies.PMID:38530662 | DOI:10.55563/clinexprheumatol/s3pvx0 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 26, 2024 Category: Rheumatology Authors: Kathrin Kramer Ann-Christin Pecher Joerg Henes Reinhild Klein Source Type: research

Effectiveness of tofacitinib monotherapy for patients with IgG4-RD or idiopathic retroperitoneal fibrosis
CONCLUSIONS: Tofacitinib is a potentially effective treatment for IgG4-RD and IRF and it is reasonable to conduct clinical trial to validate its efficacy. The JAKs were expressed in the inflammatory lesions of IgG4-RD and IRF and they may share a common pathogenesis pathway that is independent of IgG4 production.PMID:38530663 | DOI:10.55563/clinexprheumatol/61mt03 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 26, 2024 Category: Rheumatology Authors: Xiaoyu Cao Shaoxiang Li Jin Wan Zhibo Yu Gehong Dong Wei Zhou Source Type: research

Factors associated of long-term retention rate of Janus kinase inhibitors in a multi-failure rheumatoid arthritis population
CONCLUSIONS: In conclusion, our study supports the clinical effectiveness of JAKi in RA, even in the multi-failure subgroup of patients, where the risk/benefit ratio overcomes the safety risk. The presence of ACPA and the concurrent use of + cs-DMARD may increase the survival on JAKi in the long term.PMID:38530664 | DOI:10.55563/clinexprheumatol/za0hpu (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 26, 2024 Category: Rheumatology Authors: Marco Sebastiani Alen Zabotti Bruno Biasi Sofia Cacioppo Gilda Sandri Ivan Giovannini Andreina Manfredi Luca Quartuccio Source Type: research

JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience
CONCLUSIONS: JAKi may represent an effective and safe treatment option for adult JIA patients with low/moderate disease activity, particularly in case of oligoarticular involvement.PMID:38530666 | DOI:10.55563/clinexprheumatol/4yoas8 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 26, 2024 Category: Rheumatology Authors: Cecilia B Chighizola Maria Rosa Pellico Marco Pandolfi Luca Marelli Martina Cornalba Irene Pontikaki Stefania Costi Maurizio Gattinara Achille Marino Elisabetta Miserocchi Roberto Caporali Source Type: research

Prevalence of remission in patients with rheumatoid arthritis in daily clinical practice: long-term data from a tertiary care centre
CONCLUSIONS: Most patients achieved remission at least once within the observation period and almost 50% of patients also achieved SR. This study shows that the target of achieving remission should be constantly pursued, as we were able to show that even in the fourth year of treatment, patients still achieved remission.PMID:38530668 | DOI:10.55563/clinexprheumatol/66rnqb (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 26, 2024 Category: Rheumatology Authors: Nils Gildemeister Imke Redeker Bjoern Buehring Ioana Andreica David Kiefer Xenofon Baraliakos Juergen Braun Uta Kiltz Source Type: research

Anti-SSA Ro52 and anti-Ro60 autoantibodies: association with clinical phenotypes
CONCLUSIONS: Anti-Ro52+ antibody alone is frequently found in patients with non-rheumatic diseases. In addition, anti-Ro52+ antibody is also prevalent in patients with CTD and associated with clinical phenotypes that are different from anti-Ro60+ antibody.PMID:38530658 | DOI:10.55563/clinexprheumatol/puxml7 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 26, 2024 Category: Rheumatology Authors: Carolina Mazeda Natacha Oliveira Catarina Abreu Vanessa Fraga Isabel Maduro Andr é Saraiva Lu ís Inês Carla Ferreira Ana Margarida Correia Rafaela Nicolau Filipa Farinha Ingrid Villanueva Diogo Jesus Pedro Abreu Agna Neto Joana Silva Dinis Anabela Barc Source Type: research

Detection of IgE-autoantibodies to nuclear antigens in patients with systemic sclerosis and analysis of their clinical relevance
CONCLUSIONS: IgE-autoantibodies against CENP-A/B and topo-I occur in SSc underlining the concept that SSc may be a T helper cell type 2 mediated disease. IgE-anti-CENP-A-antibodies correlated with disease activity, but this has to be confirmed in larger studies.PMID:38530662 | DOI:10.55563/clinexprheumatol/s3pvx0 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 26, 2024 Category: Rheumatology Authors: Kathrin Kramer Ann-Christin Pecher Joerg Henes Reinhild Klein Source Type: research